Tests BPC 157 (IP or topical cream) for muscle crush injury of the rat gastrocnemius complex at multiple time points (2 hours to 14 days). BPC 157 accelerated healing macroscopically (less hematoma and edema, no contracture), microscopically, functionally (restored strength), and biochemically (normalized creatine kinase, LDH, AST, ALT—markers of muscle injury). Both systemic and local delivery were effective. Establishes BPC 157 as an effective therapy for blunt muscle trauma, applicable by both injection and topical routes.
Abstract
PURPOSE: Stable gastric pentadecapeptide BPC 157 accelerates the healing of a transected Achilles tendon and a transected quadriceps muscle. It may also be of clinical relevance as a systemic and local peptide treatment for crush injury of a major muscle, such as gastrocnemius muscle complex. BPC 157 is effective without a carrier, and it is presently undergoing trials for inflammatory bowel disease, and no toxicity has so far been reported.
METHODS: In crushed rats (force delivered 0.727 Ns/cm2), BPC 157 was applied either intraperitoneally or locally, as a thin cream layer, immediately after injury (sacrifice at 2 h), and once a day for 14 days.
RESULTS: BPC 157 improved muscle healing, macroscopically (less hematoma and edema, no post-injury leg contracture), microscopically, functionally, and also based on enzyme activity (creatine kinase, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase).
CONCLUSION: BPC 157, at all investigated intervals, given locally or intraperitoneally, accelerated post-injury muscle healing and also helped to restore the full function.